Please login to the form below

Not currently logged in
Email:
Password:

Pfizer generic on hold until 2019

A US district court has ruled against Teva Pharmaceuticals marketing a generic version of Viagra until its Pfizer patent expires in October 2019
A US district court has ruled against Teva Pharmaceuticals marketing a generic version of Viagra until its Pfizer patent expires in October 2019.

Israel-based Teva had claimed Pfizer's patent on Viagra (sildenafil) wasn't valid and couldn't be enforced. It also claimed that Pfizer intentionally withheld documents from the US Patent and Trademark Office.

But US Judge Rebecca Smith, Virginia said that Teva had presented no clear and convincing evidence to support this, in a 110-page opinion.

The decision was made at the end of a two-week non-jury trial. It protects Pfizer's $1bn a year in US Viagra sales.

Pfizer has noted that the decision is subject to appeal. Litigation on the same patent against other companies remains pending.

16th August 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Create Health

A healthcare marketing agency that shares your passion for making things better. Our clients with solve real health problems every...

Latest intelligence

ema1
The European Medicines Agency: PRIME’d for access?
Leela Barham examines the impact of the EMA's PRIME fast track system after two years...
How can pharma engage with key stakeholders on NHS service transformation?
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare consulting team, explain how pharma should make its case for change...
michael elliot
The race for an HIV ‘cure’
Supercharging therapies as pharma and patients work together...

Infographics